Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Department of Cancer Genetics
49 publications found
Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
Mol Imaging Biol, 21 (2), 391-398
DOI 10.1007/s11307-018-1226-7, PubMed 29916117
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
Nat Commun, 10 (1), 3407
DOI 10.1038/s41467-019-11276-9, PubMed 31431620
Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma
Blood, 134 (Supplement_1), 20
DOI 10.1182/blood-2019-128403, PubMed 31723999
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
J Mammary Gland Biol Neoplasia, 24 (2), 163-175
DOI 10.1007/s10911-018-09423-x, PubMed 30613869
Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
Pancreatology, 19 (2), 316-324
DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation
Nat Commun, 10 (1), 1749
DOI 10.1038/s41467-019-09828-0, PubMed 30988298
Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma
Aging (Albany NY), 11 (16), 6312-6335
DOI 10.18632/aging.102189, PubMed 31434796
Two truncating variants in FANCC and breast cancer risk
Sci Rep, 9 (1), 12524
DOI 10.1038/s41598-019-48804-y, PubMed 31467304
Genome-wide association study of germline variants and breast cancer-specific mortality
Br J Cancer, 120 (6), 647-657
DOI 10.1038/s41416-019-0393-x, PubMed 30787463
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Nat Commun, 10 (1), 1741
DOI 10.1038/s41467-018-08053-5, PubMed 30988301
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
JASPAR 2020: update of the open-access database of transcription factor binding profiles
Nucleic Acids Res (in press)
DOI 10.1093/nar/gkz1001, PubMed 31701148
Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers
Breast Cancer Res, 21 (1), 85
DOI 10.1186/s13058-019-1170-8, PubMed 31366361
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res (in press)
DOI 10.1093/nar/gkz1016, PubMed 31642479
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res (in press)
DOI 10.1093/nar/gkz885, PubMed 31598695
A map of direct TF-DNA interactions in the human genome
Nucleic Acids Res, 47 (4), e21
DOI 10.1093/nar/gky1210, PubMed 30517703
Identification of novel cerebellar developmental transcriptional regulators with motif activity analysis
BMC Genomics, 20 (1), 718
DOI 10.1186/s12864-019-6063-9, PubMed 31533632
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Mol Oncol, 13 (12), 2604-2615
DOI 10.1002/1878-0261.12571, PubMed 31505091
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124
High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
Theranostics, 9 (8), 2183-2197
DOI 10.7150/thno.30834, PubMed 31149037
Shared heritability and functional enrichment across six solid cancers
Nat Commun, 10 (1), 431
DOI 10.1038/s41467-018-08054-4, PubMed 30683880
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Microvessel density in breast cancer: the impact of field area on prognostic informativeness
J Clin Pathol, 72 (4), 304-310
DOI 10.1136/jclinpath-2018-205536, PubMed 30630872
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows
Clin Chem (in press)
DOI 10.1373/clinchem.2019.306837, PubMed 31628139
A Computational Framework for Genome-wide Characterization of the Human Disease Landscape
Cell Syst, 8 (2), 152-162.e6
DOI 10.1016/j.cels.2018.12.010, PubMed 30685436
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
Microrna, 8 (2), 155-165
DOI 10.2174/2211536608666181206124922, PubMed 30520388
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities
Metabolites, 9 (11)
DOI 10.3390/metabo9110278, PubMed 31766128
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
J Natl Cancer Inst, 111 (11), 1202-1215
DOI 10.1093/jnci/djz051, PubMed 30990221
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nature, 566 (7742), E1
DOI 10.1038/s41586-019-0883-2, PubMed 30659290
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972
GLI1-induced mammary gland tumours are transplantable and maintain major molecular features
Int J Cancer
DOI 10.1002/ijc.32522, PubMed 31219615
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
Beware the Jaccard: the choice of similarity measure is important and non-trivial in genomic colocalisation analysis
Brief Bioinform (in press)
DOI 10.1093/bib/bbz083, PubMed 31624847
Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma
JCO Clin Cancer Inform, 3, 1-16
DOI 10.1200/CCI.18.00102, PubMed 31070984
EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
PLoS One, 14 (1), e0204186
DOI 10.1371/journal.pone.0204186, PubMed 30703089
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Int J Epidemiol, 48 (3), 795-806
DOI 10.1093/ije/dyy201, PubMed 30277539
The circular RNome of primary breast cancer
Genome Res, 29 (3), 356-366
DOI 10.1101/gr.238121.118, PubMed 30692147
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636
A Bayesian two-way latent structure model for genomic data integration reveals few pan-genomic cluster subtypes in a breast cancer cohort
Bioinformatics, 35 (23), 4886-4897
DOI 10.1093/bioinformatics/btz381, PubMed 31077301
Simulated ablation for detection of cells impacting paracrine signalling in histology analysis
Math Med Biol, 36 (1), 93-112
DOI 10.1093/imammb/dqx022, PubMed 29452382
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma
Oncol Rep, 42 (2), 763-774
DOI 10.3892/or.2019.7186, PubMed 31173253
SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
Mol Oncol, 13 (5), 1235-1248
DOI 10.1002/1878-0261.12482, PubMed 30924596
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
Epigenetics, 14 (2), 118-129
DOI 10.1080/15592294.2019.1573066, PubMed 30665327
Subtype-Specific Transcriptional Regulators in Breast Tumors Subjected to Genetic and Epigenetic Alterations
Bioinformatics (in press)
DOI 10.1093/bioinformatics/btz709, PubMed 31529022
The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
Mol Oncol, 13 (5), 1166-1179
DOI 10.1002/1878-0261.12475, PubMed 30854794